Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-05-22 15:12:50 UTC |
---|
Update Date | 2021-09-14 15:40:23 UTC |
---|
HMDB ID | HMDB0003318 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | 4b-Hydroxystanozolol |
---|
Description | 4b-Hydroxystanozolol is a metabolite of stanozolol. Stanozolol has the potential for misuse as an anabolic steroid in horse racing. Stanozolol is an anabolic steroid illicitly used for growth promoting purposes in animal production. For reasons of public health the use of anabolic steroids as growth promoters is officially banned in Europe in animals intended for consumption. Stanozolol is a synthetic anabolic androgenic steroid often abused in sports to enhance performance. Doping control screening for the analysis of anabolic steroids in human urine or the detection of anabolic steroid residues in cattle's urine is achieved using liquid and gas chromatography time-of-flight mass spectrometry, liquid chromatography-tandem mass spectrometry or through a combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry. (PMID: 16040239 , 17724580 , 17610244 , 15782394 ). |
---|
Structure | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])[C@@H](O)C3=C(C[C@]12C)C=NN3 InChI=1S/C21H32N2O2/c1-19-10-12-11-22-23-17(12)18(24)16(19)5-4-13-14(19)6-8-20(2)15(13)7-9-21(20,3)25/h11,13-16,18,24-25H,4-10H2,1-3H3,(H,22,23)/t13-,14+,15+,16+,18-,19-,20+,21+/m1/s1 |
---|
Synonyms | Value | Source |
---|
(4b,5a,17b)-17-Methyl-2'H-androst-2-eno[3,2-c]pyrazole-4,17-diol | HMDB | 4b-OH-Stanozolol | HMDB | 4beta-Hydroxystanozolol | HMDB | Cyclopenta[7,8]phenanthro[2,3-c]pyrazole 2'H-androst-2-eno[3,2-c]pyrazole-4,17-diol deriv. | HMDB |
|
---|
Chemical Formula | C21H32N2O2 |
---|
Average Molecular Weight | 344.491 |
---|
Monoisotopic Molecular Weight | 344.246378278 |
---|
IUPAC Name | (1S,2R,9R,10R,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icosa-4(8),5-diene-9,17-diol |
---|
Traditional Name | (1S,2R,9R,10R,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icosa-4(8),5-diene-9,17-diol |
---|
CAS Registry Number | 125636-92-2 |
---|
SMILES | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])[C@@H](O)C3=C(C[C@]12C)C=NN3 |
---|
InChI Identifier | InChI=1S/C21H32N2O2/c1-19-10-12-11-22-23-17(12)18(24)16(19)5-4-13-14(19)6-8-20(2)15(13)7-9-21(20,3)25/h11,13-16,18,24-25H,4-10H2,1-3H3,(H,22,23)/t13-,14+,15+,16+,18-,19-,20+,21+/m1/s1 |
---|
InChI Key | OCUSYXNRARMJHS-SUVJOWDWSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Estrane steroids |
---|
Direct Parent | Estrane steroids |
---|
Alternative Parents | |
---|
Substituents | - Estrane-skeleton
- 4-hydroxysteroid
- Hydroxysteroid
- 17-hydroxysteroid
- Azole
- Cyclic alcohol
- Pyrazole
- Tertiary alcohol
- Heteroaromatic compound
- Secondary alcohol
- Organoheterocyclic compound
- Azacycle
- Alcohol
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
4b-Hydroxystanozolol,1TMS,isomer #1 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O)C5=C(C=N[NH]5)C[C@]4(C)[C@H]3CC[C@@]21C | 3216.9 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,1TMS,isomer #2 | C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O[Si](C)(C)C)C5=C(C=N[NH]5)C[C@]4(C)[C@H]3CC[C@@]21C | 3165.3 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,1TMS,isomer #3 | C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O)C5=C(C=NN5[Si](C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3194.0 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,2TMS,isomer #1 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O[Si](C)(C)C)C5=C(C=N[NH]5)C[C@]4(C)[C@H]3CC[C@@]21C | 3143.2 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,2TMS,isomer #2 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O)C5=C(C=NN5[Si](C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3178.6 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,2TMS,isomer #3 | C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O[Si](C)(C)C)C5=C(C=NN5[Si](C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3141.0 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,3TMS,isomer #1 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O[Si](C)(C)C)C5=C(C=NN5[Si](C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3149.7 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,3TMS,isomer #1 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O[Si](C)(C)C)C5=C(C=NN5[Si](C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3206.5 | Standard non polar | 33892256 | 4b-Hydroxystanozolol,3TMS,isomer #1 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O[Si](C)(C)C)C5=C(C=NN5[Si](C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3319.2 | Standard polar | 33892256 | 4b-Hydroxystanozolol,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O)C5=C(C=N[NH]5)C[C@]4(C)[C@H]3CC[C@@]21C | 3467.6 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1C2=C(C=N[NH]2)C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O)[C@@H]3CC[C@@H]12 | 3423.7 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1N=CC2=C1[C@H](O)[C@@H]1CC[C@H]3[C@@H]4CC[C@](C)(O)[C@@]4(C)CC[C@@H]3[C@@]1(C)C2 | 3418.2 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C2=C(C=N[NH]2)C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O[Si](C)(C)C(C)(C)C)[C@@H]3CC[C@@H]12 | 3645.6 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CC[C@H]4[C@@H](O)C5=C(C=NN5[Si](C)(C)C(C)(C)C)C[C@]4(C)[C@H]3CC[C@@]21C | 3619.9 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@H]1C2=C(C=NN2[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O)[C@@H]3CC[C@@H]12 | 3578.5 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C2=C(C=NN2[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O[Si](C)(C)C(C)(C)C)[C@@H]3CC[C@@H]12 | 3750.9 | Semi standard non polar | 33892256 | 4b-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C2=C(C=NN2[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O[Si](C)(C)C(C)(C)C)[C@@H]3CC[C@@H]12 | 3981.8 | Standard non polar | 33892256 | 4b-Hydroxystanozolol,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1C2=C(C=NN2[Si](C)(C)C(C)(C)C)C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O[Si](C)(C)C(C)(C)C)[C@@H]3CC[C@@H]12 | 3580.0 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - 4b-Hydroxystanozolol GC-MS (Non-derivatized) - 70eV, Positive | splash10-00or-0359000000-0f134279c73ede2dfb19 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4b-Hydroxystanozolol GC-MS (2 TMS) - 70eV, Positive | splash10-00di-2013900000-570ee78d58d7e1f57eeb | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4b-Hydroxystanozolol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4b-Hydroxystanozolol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 10V, Positive-QTOF | splash10-004i-0009000000-072017f9a5446fbf31a1 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 20V, Positive-QTOF | splash10-0a6r-2079000000-cc0727df2fc91ce42e51 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 40V, Positive-QTOF | splash10-0udr-9513000000-d38b2a43ed8ef01cf863 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 10V, Negative-QTOF | splash10-0006-0009000000-c5c4fa8fa856784dd5f5 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 20V, Negative-QTOF | splash10-00ov-0019000000-b88ee2c0dfea5cb32728 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 40V, Negative-QTOF | splash10-004i-2049000000-33814ebb11889f38fe27 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 10V, Negative-QTOF | splash10-0006-0009000000-f0c9f6f6d6de10398e83 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 20V, Negative-QTOF | splash10-0006-0009000000-b6d1574e79022e9c9f59 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 40V, Negative-QTOF | splash10-052f-0019000000-24be4b8b2ce190c4242a | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 10V, Positive-QTOF | splash10-0002-0019000000-a9ee0abfecf2da386d7b | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 20V, Positive-QTOF | splash10-000i-2794000000-ea9b314b90ba7e8c6771 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4b-Hydroxystanozolol 40V, Positive-QTOF | splash10-014i-1290000000-2f1310462383fa6e8904 | 2021-09-24 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023137 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 30776560 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Not Available |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 53477768 |
---|
PDB ID | Not Available |
---|
ChEBI ID | Not Available |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Hungerford NL, Sortais B, Smart CG, McKinney AR, Ridley DD, Stenhouse AM, Suann CJ, Munn KJ, Sillence MN, McLeod MD: Analysis of anabolic steroids in the horse: development of a generic ELISA for the screening of 17alpha-alkyl anabolic steroid metabolites. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):317-34. [PubMed:16040239 ]
- Mateus-Avois L, Mangin P, Saugy M: Use of ion trap gas chromatography-multiple mass spectrometry for the detection and confirmation of 3'hydroxystanozolol at trace levels in urine for doping control. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 25;816(1-2):193-201. [PubMed:15664350 ]
- Georgakopoulos CG, Vonaparti A, Stamou M, Kiousi P, Lyris E, Angelis YS, Tsoupras G, Wuest B, Nielen MW, Panderi I, Koupparis M: Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids. Rapid Commun Mass Spectrom. 2007;21(15):2439-46. [PubMed:17610244 ]
- Pozo OJ, Van Eenoo P, Deventer K, Delbeke FT: Development and validation of a qualitative screening method for the detection of exogenous anabolic steroids in urine by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2007 Oct;389(4):1209-24. Epub 2007 Aug 28. [PubMed:17724580 ]
- Van Poucke C, Van De Velde M, Van Peteghem C: Combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry for the detection of 21 anabolic steroid residues in bovine urine. J Mass Spectrom. 2005 Jun;40(6):731-8. [PubMed:15782394 ]
|
---|